Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The contribution of the lateral hypothalamic/perifornical (LH/PFx) area in mediating central effects of
corticotropin-releasing factor
(
CRF
) on cardiovascular and behavioral activity was assessed by monitoring blood pressure, heart rate and behavioral responses for a 45-min period after injections of various doses of
CRF
into the LH/PFx region or the lateral cerebral ventricle (intracerebroventricular, i.c.v.) in conscious, unrestrained rats in a familiar environment. After LH/PFx injection,
CRF
(3 and 30 ng) dose-dependently induced behavioral activation, predominantly consisting of grooming, eating and locomotor activity. Concomitantly, dose-related increases in mean arterial pressure (delta
MAP
) and heart rate (delta HR) were observed. Increases in
MAP
and HR following injection of 3 ng
CRF
were associated with the paroxysmal occurrence of behavioral activation and as such superimposed on
CRF
-induced elevation of baseline
MAP
and HR. Thirty nanograms
CRF
given i.c.v. produced grooming behavior similar to that observed after the same dose injected into the LH/PFx region, but failed to induce significant changes in cardiovascular concomitants. Rats receiving 100 ng
CRF
i.c.v., showed a significant increase in behavioral activity, respective to rats treated with 30 ng
CRF
in the LH/PFx, the tachycardiac responses, however, being similar in these groups. Both doses of
CRF
i.c.v. failed to induce significant delta
MAP
. The effects of
CRF
on cardiovascular and behavioral activity were more marked when the peptide was injected into the caudal part of the LH than those measured after administration into the rostral LH. Similarly, injections of
CRF
around or dorsal to the fornix (PFx) were more effective than those located ventrally to it. This site specificity of
CRF
-evoked responses was reflected in differential time response relations of the various effects. In summary, when i.c.v. is the route of administration, a higher dose of
CRF
is required to induce autonomic and behavioral responses similar to those elicited by
CRF
injected into the LH/PFx. The cardiovascular and behavioral effects of LH/PFx-
CRF
indicate that this region may be an important site for central
CRF
to produce stress-related autonomic and behavioral responses. In addition, the
CRF
-induced effects, both in magnitude and onset, show site specificity, the caudal LH and perifornical area being more responsive to the peptide than the rostral LH and the area ventral to the Fx. As
CRF
-evoked behavioral activation does not necessarily coincide with changes in
MAP
and HR, our data suggest a dissociation of the peptide's central actions to influence behavioral and autonomic responses.
...
PMID:Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats. 148 7
Adrenocorticotropin (ACTH), cortisol, and vasopressin responses to clamped decreases in blood pressure (
MAP
) and to ovine
corticotropin-releasing factor
(
CRF
) infusion (20 ng X kg-1 X min-1) in intact and neurohypophysectomized (NHX) conscious dogs were examined. Mean arterial blood pressure was decreased 28 mmHg by a controlled infusion of sodium nitroprusside. Hypotension induced large increases in ACTH (peak 164 +/- 25 pg/ml), cortisol (peak 12.5 +/- 2.5 micrograms/dl), and vasopressin (peak 221 +/- 64 pg/ml) in intact (n = 7) dogs. NHX (n = 7) significantly attenuated these responses to hypotension.
CRF
infusion induced increases in ACTH similar in intact (n = 4) and NHX (n = 4) dogs. However, cortisol responses were significantly attenuated by NHX. Interestingly,
CRF
infusion induced small but significant increases in vasopressin from 3.0 +/- 1.1 to 8.1 +/- 2.0 pg/ml. We conclude that NHX attenuates ACTH and vasopressin responses to hypotension and cortisol responses to
CRF
-induced increases in ACTH.
CRF
seems to stimulate vasopressin release.
...
PMID:Control of ACTH and vasopressin in neurohypophysectomized conscious dogs. 299 97
Urocortin 3 (Ucn3) is a new member of the
corticotropin-releasing factor
(
CRF
) peptide family and is considered to be a specific and endogenous ligand for
CRF
type 2 receptors (CRF2Rs). The presence of
CRF
(2)Rs has been reported in the nucleus tractus solitarius (NTS) of the rat. It was hypothesized that the activation of CRF2Rs in the medial NTS (mNTS) may play a role in cardiovascular regulation. This hypothesis was tested in urethane-anesthetized, artificially ventilated, adult male Wistar rats. Microinjections (100 nl) of Ucn3 (0.03, 0.06, 0.12, and 0.25 mM) into the mNTS of anesthetized rats elicited decreases in mean arterial pressure (
MAP
: 5.0 +/- 1.0, 21.6 +/- 2.6, 20.0 +/- 2.8, and 12.7 +/- 3.4 mmHg, respectively) and heart rate (HR: 7.8 +/- 2.6, 46.2 +/- 9.3, 34.5 +/- 8.4, and 16.6 +/- 4.9 beats/min, respectively). Microinjections of artificial cerebrospinal fluid (100 nl) into the mNTS did not elicit cardiovascular responses. Maximum decreases in
MAP
and HR were elicited by 0.06 mM concentration of Ucn3. Cardiovascular responses to Ucn3 were similar in unanesthetized midcollicular decerebrate rats. A bilateral vagotomy completely abolished Ucn3-induced bradycardia. The decreases in
MAP
and HR elicited by Ucn3 (0.06 mM) were completely blocked by astressin (1 mM; nonselective CRFR antagonist) and K41498 (5 mM; selective CRF2R antagonist). Microinjections of Ucn3 (0.06 mM) into the mNTS decreased the efferent greater splanchnic nerve activity. After the blockade of CRF2Rs in the mNTS, a Ucn3-induced decrease in the efferent sympathetic nerve discharge was abolished. These results indicate that Ucn3 microinjections into the mNTS exerted excitatory effects on the mNTS neurons via CRF2Rs, leading to depressor and bradycardic responses.
...
PMID:Cardiovascular responses to microinjections of urocortin 3 into the nucleus tractus solitarius of the rat. 1906 Jan 21